Although PD‐1/PD‐L1 blockade therapy has been a major advance in cancer immunotherapy, there are still some limitations, including the lack of a sensitive, accurate biomarker to predict response sensitivity and prognosis in cancer patients.11 Here, PDCD1 is linked to cancer.